Immunocore Ltd of Oxford, UK has secured another partnership with a major pharmaceutical company relating to the exploitation of its recombinant T cell receptor technology platform – this time with Eli Lilly and Company.
Immatics Biotechnologies GmbH has received €22 million from its venture capital investors – the final tranche in a Series D round that will enable it to complete a Phase 3 trial of a cancer vaccine for renal cell carcinoma, a type of kidney cancer.
The Board of Shire Plc has responded favourably to a revised takeover proposal from AbbVie Inc which values Shire at £53.20 per share, up from £51.15 per share earlier. The board is in detailed discussions with the US company about other terms of the proposed deal.
Salix Pharmaceuticals Inc is the latest company to take advantage of low corporate tax rates in Ireland through its planned merger with the Irish subsidiary of Cosmo Pharmaceuticals SpA of Italy. The transaction is expected to close in the fourth quarter.
A UK-based drug services company, Ergomed Plc, is to be admitted to the Alternative Investment Market of the London Stock Exchange following a fundraising of £11 million. Shares in the company are expected to start trading on 15 July.
ArGEN-X NV, which is developing antibody therapeutics for cancer and autoimmune diseases, has raised €40 million in an initial public offering on the Euronext stock exchange in Brussels. If over-allotment options are exercised in full, total proceeds will rise to €44 million.
Shire Plc has urged its shareholders not to act in response to a new cash and share takeover proposal from AbbVie Inc that values the company at about £51.15 per share, up by 11% from £46.26 per share earlier. The proposal is AbbVie’s fourth for the Dublin-based company.
Life Sciences Partners (LSP) BV of the Netherlands is leading a €4.4 million Series A financing round for privately-held Mint Solutions Holding BV which has developed technology for verifying that drugs administered in a hospital correctly match their prescriptions.
Premaitha Health Plc, which is developing a prenatal test for genetic disorders such as Down’s syndrome, has made its debut on the AIM market of the London Stock Exchange in a transaction that involved a reverse takeover, a name change, a reverse split and additional finance.
Abzena Plc, which provides services to companies developing biopharmaceuticals, has conditionally raised £20 million through the placement of new shares in conjunction with its forthcoming listing on the Alternative Investment Market of the London Stock Exchange.